This site uses cookies for technical purposes as specified in the cookie policy.
If you want to learn more or opt out of all or some cookies, see the cookie policy.
By closing the banner or continuing to browse, you consent to the use of cookies.
Scientific Insights
Projects
The central nervous system tissue, subject to recurrent and/or chronic neuroinflammatory conditions of different origin, tends to exhaust its own capability to synthesize the endogenous Palmitoylethanolamide while, at the same time, to increase the oxidative tone of the district, raising in this way the risk factor of neurodegeneration for several diseases (of degenerative, dismetabolic, traumatic origin) affecting the central nervous system. In these cases it is of great importance to counteract the activation process of non neuronal cells (astroglia and microglia) whose normal function is to guarantee the homeodynamic balance of the nervous tissue.
Ultra-micronized Palmitoylethanolamide, has shown acting in the body as a biological modulator of neuroinflammation, promoting the control of the physiological reactivity of the central nervous tissue. International scientific literature has widely demonstrated that the combination of ultra-micronized Palmitoylethanolamide and Luteolin (PEALUT®) contributes to the normal functioning of the central nervous system, with particular benefits on cognitive function and mood.
Bibliografia
Assogna M. et al. Synaptic Effects of Palmitoylethanolamide in Neurodegenerative Disorders. Biomolecules. 2022
Bonzanino M. et al. PEALut in the Dietary Management of Patients with Acute Ischemic Stroke: A Prospective Randomized Controlled Clinical Trial. J. Clin. Med. 2024
Caltagirone C. et al. Co-ultramicronized palmitoylethanolamide/luteolin in the treatment of cerebral ischemia: from rodent to man. Transl Stroke Res. 2016
Colizzi M. et al. Therapeutic effect of palmitoylethanolamide in cognitive decline: A systematic review and preliminary meta-analysis of preclinical and clinical evidence. Front. Psychiatry 2022
Cordaro M. et al. An Update of Palmitoylethanolamide and Luteolin Effects in Preclinical and Clinical Studies of Neuroinflammatory Events. Antioxidants. 2020
De Gregorio D. et al. Role of palmitoylethanolamide (PEA) in depression: Translational evidence: Special Section on “Translational and Neuroscience Studies in Affective Disorders”. J Affect Disord. 2019
Petrosino S. et al. Oral Ultramicronized Palmitoylethanolamide: Plasma and Tissue Levels and Spinal Anti-hyperalgesic Effect. Front. Pharmacol. 2018
Petrosino S. et al. Palmitoylethanolamide: A Nutritional Approach to Keep Neuroinflammation within Physiological Boundaries. A Systematic Review. Int J Mol Sci. 2020
Scuderi C. et al. Ultramicronized palmitoylethanolamide rescues learning and memory impairments in a triple transgenic mouse model of Alzheimer’s disease by exerting anti-inflammatory and neuroprotective effects. Transl Psychiatry. 2018
The access to the web site and to its content is only for personal use and purposes (i.e. for personal information, research or study).
Without prejudice to any right, faculty or authority of third parties, in case of prohibited conduct Epitech Group SpA shall reserve the right to act according to the law.